Aligos Therapeutics, Inc.
NASDAQ: ALGS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lawrence Blatt
- Employees
- 70
- Headquarters
- South San Francisco, United States
- IPO year
- 2020
- Market cap
- $34.5M
- Website
- https://www.aligos.com
Loading ALGS…
Loading profile data…Frequently asked questions about ALGS
What does Aligos Therapeutics, Inc. (ALGS) do?
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical t...
Where does ALGS trade?
Aligos Therapeutics, Inc. (ALGS) trades on the NASDAQ Global Select.
What sector is ALGS in?
Aligos Therapeutics, Inc. (ALGS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aligos Therapeutics, Inc.?
Lawrence Blatt is the chief executive officer of Aligos Therapeutics, Inc. (ALGS).
Where is Aligos Therapeutics, Inc. headquartered?
Aligos Therapeutics, Inc. is headquartered in United States.
Does ALGS pay a dividend?
Aligos Therapeutics, Inc. (ALGS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALGS go public?
Aligos Therapeutics, Inc. (ALGS) completed its initial public offering in 2020.